Inmune Bio, Inc.
Inmune Bio, Inc. (INMB): 4 pipeline candidates · ~19 mo cash runway · 5 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
19.2 months
D/E 0.32 · 0% dilution
Lead: Phase 3
4 candidates
N/A
N/A
A transparent, data-derived signal for Inmune Bio, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$34.6M
Cash
$21.4M
Quarterly Burn
$3.4M
Runway
19.2 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
81
Total value held
$7.1M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 1,374,030 | $1.6M |
| blackrock, inc. | 1,194,112 | $1.3M |
| geode capital management, llc | 494,969 | $559K |
| eversource wealth advisors, llc | 4,295 | $427K |
| state street corp | 290,879 | $329K |
| aqr capital management llc | 270,317 | $305K |
| susquehanna international group, llp | 243,191 | $275K |
| goldman sachs group inc | 231,586 | $262K |
| raymond james financial inc | 203,245 | $230K |
| northern trust corp | 184,225 | $208K |
Showing top 10 of 81 institutional holders of Inmune Bio, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Inmune Bio, Inc.'s pipeline?
Inmune Bio, Inc. (INMB) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Inmune Bio, Inc.'s lead drug candidate?
Inmune Bio, Inc.'s most advanced tracked candidate is cordstrom (Phase 3) for Recessive Dystrophic Epidermolysis Bullosa (RDEB).
What is Inmune Bio, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Inmune Bio, Inc. has approximately 19.2 months of cash runway.
What is Inmune Bio, Inc.'s market capitalization?
Inmune Bio, Inc.'s market capitalization is approximately $34.6M.
Who is the CEO of Inmune Bio, Inc.?
Mr. David J. Moss M.B.A. is the chief executive officer of Inmune Bio, Inc. (INMB).
Get the full picture on Inmune Bio, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.